This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Oncodesign Sa. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Aurélien Tap: Innovator in Macrocyclic Kinase Inhibitors
Introduction
Aurélien Tap is a notable inventor based in Saulx les Chartreux, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of kinase inhibitors. His work focuses on innovative compounds that have the potential to impact the diagnosis and treatment of various diseases.
Latest Patents
Aurélien Tap holds a patent for "Macrocyclic RIP2-kinase inhibitors." This invention relates to macrocyclic compounds and compositions that act as kinase inhibitors, specifically targeting RIP2-kinase and its mutants. The patent outlines methods for using these compounds as medicines or diagnostic agents, emphasizing their role in addressing RIP2-kinase associated diseases. The patent includes a compound according to Formula(I) and its various forms, such as stereoisomers and salts. He has 1 patent to his name.
Career Highlights
Aurélien Tap is associated with Oncodesign SA, a company that specializes in drug discovery and development. His work at Oncodesign has allowed him to explore innovative solutions in the field of oncology and beyond. His research has contributed to advancing the understanding of kinase inhibitors and their therapeutic applications.
Collaborations
Throughout his career, Aurélien has collaborated with talented professionals, including Yann Lamotte and Nérina Dodic. These collaborations have fostered a dynamic research environment, enhancing the development of new therapeutic strategies.
Conclusion
Aurélien Tap is a distinguished inventor whose work on macrocyclic RIP2-kinase inhibitors showcases his commitment to advancing medical science. His contributions have the potential to lead to significant breakthroughs in the treatment of diseases associated with RIP2-kinase.